Abstract
Introduction
Lung cancer is increasingly a disease of older patients. The median age of diagnosis is 70, and one in three patients is aged 75 years or older (1) . Although lung cancer incidence rates are stable or falling in many countries, this has been offset by the expansion of the elderly demographic, resulting in an overall increase in the number of elderly patients with lung cancer (1) (2) (3) . For example, in Canada the age-standardized incidence rates for lung cancer have Elderly patients are less likely to receive protocol-specified treatment, often due to concerns about comorbidity, frailty, or efficacy (1;6;7). Almost 70% of elderly lung cancer patients have significant comorbidities, compared to about 50% of younger patients (8) .
Physiologic changes that occur with aging may alter the efficacy or toxicity of treatment (9) .
Post-operative risks are higher in elderly patients, particularly those with impaired performance status (3;10). Non-surgical options, such as conventional external beam radiotherapy (RT) have historically demonstrated inferior outcomes when compared to surgery (11;12) , with only small improvements in median survival compared to no treatment (13) . This has led to instances of medically inoperable elderly patients being deferred treatment until development of symptoms (12) .
Elderly patients are less often subjects of clinical trials (14;15) , leading to more uncertainty about optimal management, and a greater reliance on other types of comparative effectiveness studies. Several studies have examined outcomes for elderly patients with stage I NSCLC after either surgery or RT, but no large or recent studies have reported outcomes for both treatments, with curative intent, from the same baseline population. This is an important distinction, as surgical and radiotherapeutic outcomes depend highly on patient selection.
Reports on only one of these two treatment options may give an incomplete picture of outcomes for elderly patients. The aims of our study were to assess survival outcomes for elderly patients with stage I lung cancer treated with radical intent and to determine the impact of age on posttreatment survival.
Methods

Data Sources
The majority of cancer care in British Columbia, a province in excess of 4 million people, is provided by the BC Cancer Agency (BCCA). Treatment policy for lung cancer in the province is generated by the Lung Tumor Group and the treatment guidelines are published online Patients were classified by primary radical local treatment into 2 groups: surgery or RT.
Nine patients who received surgery plus adjuvant (n=8) or neoadjuvant (n=1) RT were included in the surgery group. Patients were classified as receiving radical RT if treatment intent was coded as 'radical' and they received a dose equivalent to 40 Gy in 20 fractions or higher. Since several fractionation schemes were used with a variety of fraction sizes, RT doses were normalized to 2 Gy per fraction equivalents using the linear-quadratic formula (17) . Following data analysis, the accuracy of the final dataset was assessed by a random review of the charts of 10% of patients. The database was found to be highly accurate, with only minor deviations found, none of which affected inclusion in the present study or outcomes.
Statistical Analysis
Baseline differences between the elderly (age ≥ 75) and non-elderly patients were compared using the t-test, Fisher's Exact test, or the Chi-squared test, as appropriate. Kaplan-Meier estimates of overall survival (OS) and disease-specific survival (DSS) from date of diagnosis were generated, with differences compared using the log rank test. Cox Regression analysis was used to determine the factors associated with survival outcome after the proportional hazards assumptions were confirmed. Age was considered as a continuous variable for multivariate analysis. Due to the potential for competing risks of death influencing the DSS analysis, these were confirmed using a cumulative incidence methodology (19) 
Results
The clinical characteristics of the 558 patients meeting the inclusion criteria are shown in Table   1 , stratified by age and treatment modality. In the whole cohort, 310 patients were treated with surgery and 248 with RT, of whom 211 (38%) were age 75 or older. The median follow-up for all patients was 2.4 years (range 0.1 -8.2 years). Older patients were much less likely to undergo surgery than their younger counterparts (72% of patients age < 75 vs. 43% of patients age ≥ 75, p<0.0001).
Patients treated with surgery
Of the 310 patients treated with surgery, the median age was 67 years (range 20-86 years), and 63 patients (20%) were age 75 or greater. A comparison of the older and younger age groups (shown in Table 1 ) revealed no significant differences in baseline characteristics.
There were 75 deaths among the patients treated with surgery. Estimated OS at 2 years was 87% and at 5 years was 69%. Figure 1 shows OS stratified by age category, with no significant difference between elderly and younger patients (p=0.38). In elderly patients, the OS rates were 88% at 2 years and 65% at 5 years. There were no changes in OS by era of diagnosis (Table 2A) , age was not predictive of OS, whereas tumor stage and ECOG performance status were predictive of OS.
Of the 75 deaths, 50 were due to lung cancer. DSS was 91% at 2 years and 79% at 5 years. Figure 1B shows DSS by age category, indicating a trend toward inferior DSS in the patients aged 75 or older, but this did not meet statistical significance (log-rank p=0.10). On multivariate analysis tumor stage and ECOG score were predictive of DSS, whereas age was not (Table 2B) . (Table 1 The most co Of the 174 deaths, 110 were due to lung cancer. The estimated DSS at 2 years was 65.2%
and at 5 years was 38.1%. Kaplan-Meier estimates of DSS by age category are shown in Figure 2B . There was no significant difference between the older and younger groups in DSS (p=0.15). On multivariate analysis (Table 2D) , the only factor predictive of DSS was tumor stage, whereas RT dose approached significance and age was not predictive. Although outcomes for elderly patients with stage I NSCLC are variable and strongly reflective of the baseline patient population, the OS estimates in our study are consistent with published data (21) (22) (23) . Comparisons between outcomes RT and surgery are very difficult, and were not done in this study. Although the outcomes after RT appear to be inferior to surgery, the exact difference in outcomes between the two treatments cannot be easily ascertained. with 138 patients, and reported that age did not affect post-treatment survival (27) .
Although age does not appear to predict survival in patients who receive radical treatment, age does impact upon whether patients are referred for treatment, and whether curative treatment is offered. Rates of referral and radiotherapy utilization have been shown to decrease with age (7). As a result, the patients included in studies examining outcomes after radical treatments represent a selected group that likely differs from the baseline population of elderly patients. Our data did not allow us to draw conclusions on elderly patients with stage I NSCLC who were never referred for treatment.
Treatment options for elderly patients with stage I NSCLC have evolved over the past 10 years, and newly diagnosed patients may have more options available than the patients in this cohort. Minimally invasive surgery using video-assisted thoracic surgery (VATS) decreases operative morbidity and can allow for resection in elderly patients who would otherwise be unfit for surgery (28) . Fitness for surgery and operative mortality risks can be assessed pre-operatively using validated instruments (29) . There has been a change in the RT treatment paradigm, with the delivery of large ablative doses using stereotactic body radiation therapy (SBRT). SBRT has been shown to achieve high rates of local control in elderly patients, with a good side-effect profile (30) .
The findings of this study should be considered in the context of its strengths and limitations. As is common with the use of large administrative databases, data was not recorded for all variables of interest, particularly co-morbidities, weight loss at presentation, toxicity, and quality of life. Patients with stage I disease who received palliative RT or no treatment are not included, and these patients may be more likely to be elderly (7) . The surgical data is not population-based, and elderly patients may have been less likely to be referred to a BCCA surgeon, or referred after surgery for consideration of adjuvant therapy. PET scanning was not widely available in BC until 2004, and therefore most patients in this cohort did not undergo PET scans.
In conclusion, our study shows that survival outcomes for elderly patients after radical treatment for stage I NSCLC are similar to those of younger patients, whether treated with surgery or RT. In making decisions regarding treatment for elderly patients, oncologists should consider the individual characteristics of each patient, and elderly patients who are sufficiently fit should be considered for curative treatments.
